This double-blind, placebo-controlled therapeutic exploratory trial (n=60) conducted by the University of Cyprus, investigates the efficacy of ketamine in preventing relapse in patients with Opioid-Use Disorders (OUD). The trial, named PROUD, is currently ongoing.
Status: Active, not recruiting
Start date: 2022-04-28
Phase II
Blinded
60 participants
Interventional
This randomised controlled trial (n=24) investigates the rapid alleviation of depression in individuals with coexisting alcohol dependence (AUD), utilising ketamine at sub-anaesthetic doses (7-140mg/70kg intramuscular).
Status: Not yet recruiting
Start date: 2010-09-01
Phase II
Blinded
24 participants
Interventional
This randomised, multicenter, control trial (n=352) investigates the effect of intravenous esketamine on opioid consumption and postoperative pain in female patients undergoing breast cancer surgery.
Status: Recruiting
Start date: 2021-10-07
Not Applicable
Blinded
352 participants
Interventional
This double-blind, randomised, active-comparator trial (n=80) will study the effects of psilocybin (30mg) versus ketamine (52.5mg/70kg) for alcohol use disorder (AUD).
Status: Not yet recruiting
Start date: 2024-06-01
Phase II
Blinded
80 participants
Interventional
This interventional trial (n=80) aims to investigate the effectiveness of a Ketamine Assisted Group Mindfulness intervention for Alcohol Use Disorder (AUD).
Status: Not yet recruiting
Start date: 2022-03-01
Phase II
Blinded
80 participants
Interventional
This single-group assignment trial (n=6) aims to evaluate the feasibility and preliminary efficacy of ketamine as a treatment for patients with Opioid Use Disorder (OUD) and comorbid depression (OUDCD).
Status: Recruiting
Start date: 2022-04-04
Phase I
Open
6 participants
Interventional
This pilot study (n=8) aims to assess the feasibility of using ketamine-assisted treatment for tobacco use disorder, alongside brief motivational enhancement therapy.
Status: Recruiting
Start date: 2023-05-02
Phase I
Open
8 participants
Interventional
This pilot, double-blind, placebo-controlled randomized clinical trial (n=50) led by Brigham and Women's Hospital aims to assess the safety and preliminary efficacy of ketamine (56mg/70kg) treatment for individuals with opioid use disorder (OUD) and suicidal ideation (SI) in the emergency department.
Status: Not yet recruiting
Start date: 2024-03-01
Phase II
Blinded
48 participants
Interventional
This triple-blinded, randomised, active, placebo-controlled trial (n=34) will investigate the effects of ketamine in combination with standard inpatient addiction therapy for adults suffering from depression and alcohol use disorder (AUD).
Status: Not yet recruiting
Start date: 2024-01-01
Phase I
Blinded
34 participants
Interventional
This open-label Phase II pilot study (n=20), registered on ANZCTR with the trial acronym MASKOT, investigates the safety and tolerability of sub-anaesthetic ketamine in young people with methamphetamine use disorder seeking treatment to reduce their methamphetamine use.
Status: Recruiting
Start date: 2022-03-10
Phase II
Open
20 participants
Interventional
This double-blind, randomised, controlled trial (n=280) will investigate the efficacy of ketamine-assisted psychological therapy in severe alcohol use disorder (AUD) patients.
Status: Not yet recruiting
Start date: 2023-08-30
Phase III
Blinded
280 participants
Interventional
This pilot double-blind, placebo-controlled randomized clinical trial (n=50) aims to assess the safety and preliminary efficacy of ketamine as a treatment for individuals with alcohol use disorder (AUD) seeking inpatient alcohol detoxification in the emergency department (ED).
Status: Recruiting
Start date: 2023-10-25
Phase II
Blinded
49 participants
Interventional
This Phase I/Phase II interventional trial (n=60) aims to evaluate Ketamine Assisted Psychotherapy (KAP) as an adjunct to the Mindfulness-Oriented Recovery Enhancement (MORE) intervention for Opioid Use Disorder (OUD).
Status: Recruiting
Start date: 2021-05-20
Phase I
Blinded
60 participants
Interventional
This terminated interventional trial (n=0) was conducted by the Medical University of South Carolina. The study aimed to examine whether ketamine, along with psychotherapy, is an effective treatment for depression in participants with a history of opioid addiction who have not abused opioids for at least three months.
Status: Terminated
Start date: 2022-01-13
Phase II
Open
5 participants
Interventional
This placebo-controlled, double-blind, parallel-group interventional trial (n=120) aims to explore the effects of combining ketamine with real-time functional magnetic resonance imaging (fMRI) neurofeedback training in individuals with cocaine use disorder (CUD).
Status: Recruiting
Start date: 2024-02-05
Phase II
Blinded
120 participants
Interventional
This interventional, randomised pilot feasibility study (n=44, age 18-65) aims to assess the potential of single-dose interventions (including ketamine) in reducing re-admissions for hospitalised patients with severe alcohol use disorder (AUD).
Status: Completed
Start date: 2022-01-19
Phase I
Blinded
44 participants
Interventional
This double-blind, randomized, active-comparator controlled trial (n=20) will compare the effects of psilocybin-assisted psychotherapy with ketamine-assisted psychotherapy in individuals struggling with alcohol use disorder (AUD).
Status: Recruiting
Start date: 2024-02-02
Phase II
Blinded
20 participants
Interventional
Awakn Life Sciences has announced a Phase III trial to explore the effects of ketamine-assisted therapy in the treatment of alcohol use disorder (AUD).
Status: Planned
Start date: 2023-05-01
Phase III
Blinded
280 participants
Interventional
This study will investigate whether psilocybin administered under supportive conditions can reduce illicit opioid use and improve quality of life in individuals with Opioid Use Disorder (OUD) in Methadone Maintenance Treatment (MMT) who are concurrently using other opioids illicitly.
Status: Not yet recruiting
Start date: 2022-02-16
Phase II
Blinded
92 participants
Interventional
96 recently detoxified alcoholics will be randomized to receive either 3 sessions ketamine (0.8 mg/kg IV over 45 minutes) or placebo plus manualised psychological therapy, or 3 sessions of ketamine or placebo plus simple psychoeducation.
Status: Completed
Start date: 2016-10-10
Phase II
Blinded
96 participants
Interventional
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment.
Status: Recruiting
Start date: 2020-12-17
Phase II
Blinded
30 participants
Interventional
This project aims to evaluate the potential rapid and sustained antisuicidal and antidepressant effects of a single intranasal dose of ketamine in inpatients during a mood episode in Major Depressive Disorder (MDD) or Bipolar Disorder (BD) with or without comorbid recent abuse of alcohol.
Status: Recruiting
Start date: 2008-05-01
Phase III
Blinded
50 participants
Interventional
To evaluate if naltrexone plus ketamine is effective in reducing depression and alcohol consumption.
Status: Completed
Start date: 2016-1-5
Phase II
Open
5 participants
Interventional
The investigators will compare 3 treatment groups (ketamine plus naltrexone vs. ketamine alone vs. placebo) for treating major depressive disorder (MDD) and alcohol use disorder (AUD) in an 8-week randomized, double-blind, placebo-controlled, between-subjects trial.
Status: Recruiting
Start date: 2015-1-1
Phase I
Blinded
65 participants
Interventional
This open-label trial (n=5) investigates the effects of ketamine (35mg/70kg, 4x over 4 weeks) on those suffering from depression and alcohol dependence simultaneously.
Status: Completed
Start date: 2021-03-01
Phase I
Open
5 participants
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
?>